MedTrace Logo

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01396187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-01-12

Study results available
· View outcomes & findings →

Summary

This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05231023

5 mg IV twice a week for 4 weeks

DRUG

PF-05231023

25 mg IV twice a week for 4 weeks

DRUG

PF-05231023

100 mg IV twice a week for 4 weeks

DRUG

PF-05231023

200 mg IV twice a week for 4 weeks

OTHER

Placebo

0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01396187 on ClinicalTrials.gov